Reproductive history and risk of nasopharyngeal carcinoma: A population-based case-control study in southern China.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
01 2019
Historique:
received: 18 08 2018
revised: 21 10 2018
accepted: 18 11 2018
entrez: 9 1 2019
pubmed: 9 1 2019
medline: 9 4 2020
Statut: ppublish

Résumé

Nasopharyngeal carcinoma (NPC) incidence exhibits a remarkable sex disparity, with higher risk among males. Whether this pattern can be partly explained by female reproductive history is unclear. A population-based case-control study of NPC was conducted in southern China between 2010 and 2014, including 674 histopathologically verified female NPC cases and 690 female controls randomly selected from population-based registries. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression after adjusting for potential confounders. Women who had 3, 4, or ≥5 pregnancies compared with 2 pregnancies were at significantly increased risk for NPC (ORs 1.56, 1.45 and 1.88, respectively). History of deliveries was similarly associated with a greater risk of NPC. These positive associations were more prominent in women who were younger than 50 years, had less than 10 years of education, or were white-collar workers. Increasing time since menopause was associated with a diminished NPC risk (P Contrary to our hypothesis, a history of pregnancy or delivery increased the risk of NPC and the risk decreased with increasing time since menopause. However, the non-linear relationship and no consistent risk patterns across strata indicate that the observed associations are unlikely to be causal, and may at least partially be ascribed to residual confounding by socioeconomic factors.

Identifiants

pubmed: 30616779
pii: S1368-8375(18)30444-5
doi: 10.1016/j.oraloncology.2018.11.025
pmc: PMC6336493
mid: NIHMS1514368
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-108

Subventions

Organisme : NCI NIH HHS
ID : R01 CA115873
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Références

Int J Cancer. 2000 Feb 1;85(3):364-9
pubmed: 10652428
Am J Reprod Immunol. 1982 Aug;2(4):217-21
pubmed: 6291416
Chin J Cancer. 2015 May 14;34(8):350-7
pubmed: 26058679
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1201-7
pubmed: 27197279
Curr Top Med Chem. 2006;6(2):103-11
pubmed: 16454762
Occup Environ Med. 2006 Jan;63(1):39-44
pubmed: 16361404
Reprod Toxicol. 2008 Aug;25(4):468-71
pubmed: 18534816
Immunogenetics. 2006 Apr;58(2-3):113-21
pubmed: 16547745
Cancer. 2017 Jul 15;123(14):2716-2725
pubmed: 28241094
J Virol. 1996 Oct;70(10):6816-9
pubmed: 8794321
Eur J Cancer. 2013 Jan;49(1):150-5
pubmed: 22892061
BJOG. 2005 Dec;112(12):1620-4
pubmed: 16305564
Science. 2007 Jul 6;317(5834):121-4
pubmed: 17615358
Am J Perinatol. 2010 Oct;27(9):715-9
pubmed: 20387188
Cancer Causes Control. 2015 Jun;26(6):913-21
pubmed: 25822573
J Leukoc Biol. 2002 Sep;72(3):512-21
pubmed: 12223519
Curr Opin Investig Drugs. 2006 Nov;7(11):997-1001
pubmed: 17117588
J Infect Dis. 1983 Jun;147(6):982-6
pubmed: 6304207
BMC Cancer. 2010 Aug 20;10:446
pubmed: 20727127
Oncotarget. 2017 Jul 29;8(50):87073-87085
pubmed: 29152064
Cancer Causes Control. 1999 Jun;10(3):201-7
pubmed: 10454065
Chin J Cancer. 2011 Feb;30(2):79-84
pubmed: 21272439
Vaccine. 2003 Jul 28;21(24):3352-7
pubmed: 12850338
Chin J Cancer. 2010 May;29(5):517-26
pubmed: 20426903

Auteurs

Rui-Mei Feng (RM)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Ellen T Chang (ET)

Exponent, Inc., Health Sciences Practice, Menlo Park, CA, USA; Stanford Cancer Institute, Stanford, CA, USA.

Zhiwei Liu (Z)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Qing Liu (Q)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Yonglin Cai (Y)

Department of Clinical Laboratory, Wuzhou Red Cross Hospital, Wuzhou, China; Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism, Wuzhou, China.

Zhe Zhang (Z)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China; Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.

Guomin Chen (G)

State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Qi-Hong Huang (QH)

Sihui Cancer Institute, Sihui, China.

Shang-Hang Xie (SH)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Su-Mei Cao (SM)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Yu Zhang (Y)

State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Jingping Yun (J)

State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Wei-Hua Jia (WH)

State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Yuming Zheng (Y)

Department of Clinical Laboratory, Wuzhou Red Cross Hospital, Wuzhou, China; Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism, Wuzhou, China.

Jian Liao (J)

Cangwu Institute for Nasopharyngeal Carcinoma Control and Prevention, Wuzhou, China.

Yufeng Chen (Y)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Longde Lin (L)

Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.

Ingemar Ernberg (I)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Guangwu Huang (G)

Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China; Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.

Yi Zeng (Y)

State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Yi-Xin Zeng (YX)

State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Beijing Hospital, Beijing, China.

Hans-Olov Adami (HO)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.

Weimin Ye (W)

Department of Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine & Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: yewm@sysucc.org.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH